Business
Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities
LONDON, UK / ACCESS Newswire / January 28, 2026 /THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK ...
About this update from Genflow Biosciences Plc
[{"type":"text","content":"LONDON, UK / ACCESS Newswire / January 28, 2026 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.","length":465,"tagName":"p"},{"type":"text","content":"Genflow Biosciences Plc","length":23,"tagName":"p"},{"type":"text","content":"Administrative Approval of €4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities","length":118,"tagName":"p"},{"type":"text","content":"Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces the administrative approval of the previously announced award of approximately €4 million in non-dilutive financial support from the Wallonia Region of Belgium, following the assenting signature of Minister Adrien Dolimont.","length":441,"tagName":"p"},{"type":"text","content":"The funding, once received, will support the continued development of the Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis ("MASH"). The original RNS announcing the award can be found here.","length":272,"tagName":"p"},{"type":"text","content":"Disbursement of the first instalment is expected no later than May 2026. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap. All project-related expenses incurred during 2025 will be eligible under the terms of the programme.","length":286,"tagName":"p"},{"type":"text","content":"Development Priorities for 2026","length":31,"tagName":"p"},{"type":"text","content":"In 2026 Genflow's strategy emphasises pipeline discipline and capital efficiency, prioritising programmes with the strongest data, the clearest paths to value creation, and the highest potential for partner engagement. Central to this approach is the pursuit of early-stage collaboration agreements designed to secure non-dilutive funding, ...